A new population pharmacokinetic model for dosing optimization of zonisamide in patients with refractory epilepsy.

Zonisamide exhibits significant pharmacokinetic variability, demanding for the development of population pharmacokinetic (PopPK) models to identify key factors influencing drug disposition. This study aimed to develop and validate a PopPK to optimize zonisamide posology in patients with refractory epilepsy. A total of 114 plasma concentrations of zonisamide, obtained from 64 patients, were used for PopPK model development, employing the nonlinear mixed-effects modelling approach.

Dendritic cells in triple-negative breast cancer: From pathophysiology to therapeutic applications.

Breast cancer is the second most commonly diagnosed cancer in women and the fifth leading cause of cancer-related deaths worldwide. It is a highly heterogeneous disease, consisting of multiple subtypes that vary significantly in clinical characteristics and survival outcomes. Triple-negative breast cancer (TNBC) is a particularly aggressive and challenging subtype of breast cancer.

The impact of extract on pharmacokinetics of phenytoin in rats.

Epilepsy patients are at a higher risk of developing overweight and obesity. Given the thermogenic properties of (Guarana), this study aimed to evaluate a potential pharmacokinetic interaction between extract and phenytoin in rats. Two pharmacokinetic studies were developed with and phenytoin: a coadministration and a pre-treatment study.